A clinical trial of intra-arterial infusion chemotherapy with cisplatin for head and neck cancer

A clinical trial of intra-arterial infusion chemotherapy with cisplatin for head and neck cancer - A clinical trial of intra-arterial infusion chemotherapy with cisplatin for head and neck cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017656

Enrollment

Registered

2015-05-25

Start date

2015-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck squamous cell carcinoma

Interventions

Combined therapy of intra-arterial infusion chemotherapy with cisplatin and radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Head and neck cancer 2)Stage 3, 4A, or 4B 3)Without previous irradiation for head and neck 4)Without previous chemotherapy with cisplatin 5)Squamous cell carcinoma 6)>=20, <=80 7)Performance Status(ECOG) 0-2 8)WBC >3000/mm3, Neutrophil >1500/mm3 9)Hb >9g/dL 10)PLT >=100,000/mm3 11)AST, ALT <3 times the upper limit of normal 12)total bilirubin <2mg/dL 13)Creatinine clearance >50mL/min 14)Provided written informed consent

Exclusion criteria

Exclusion criteria: 1)Prior history of radiotherapy for head and neck 2)History of serious drug allegies 3)With severe complications (hepatic disorder, renal disorder,or heart disease, bowel obstruction, peptic ulcer, severe diabetes) 4)with history of severe mental disorder 5)pregnant or nursing women or women who like be pregnant and men with partner willing to get pregnant 6)Cases that the investigator (subinvestigator) judged as inappropriate as the subject of this clinical study

Design outcomes

Primary

Measure	Time frame
maximum tolerrated dose, recommended dose	—

Secondary

Measure	Time frame
response rate, toxicity, overall survival, local control time, progression free time	—

Countries

Japan

Contacts

Public ContactYutaka Toyomasu

Mie University Hospital Department of Radiation Oncology

y-toyomasu@clin.medic.mie-u.ac.jp059-231-5029

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026